Recombinant human serum albumin versus human serum albumin in cirrhosis with ascites

Phase 3, randomised, double-blind trial of recombinant human serum albumin in Ascites in cirrhosis (2 arms), sponsored by Beijing Friendship Hospital. Primary endpoint: Change in serum albumin concentration from baseline immediately after completion of the last intravenous administration. Planned start Aug 2024; status: not yet recruiting.